Sivelestat

PreclinicalSmall molecule

Eli Lilly

Sivelestat is one of 2 small molecule programs targeting Cardiovascular Surgery. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular SurgeryRecruiting

Cardiovascular SurgeryPreclinical

Recruiting

Competition

Competitive Landscape

1 competitor in Cardiovascular Surgery

#DrugCompanyPhaseTrials

Tavist

HHALEON

Preclinical

1 2

Sivelestat

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2031

Phase 2Recruiting

Sepsis

NCT06381661

Clinical

Trials by Indication[1]

Acute Lung Injury1 trial

A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury

Completed· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT00036062·600 enrolled

Cardiovascular Surgery1 trial

Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery (PANDA VI)

Recruiting·NNanjing Medical University·N/A·NCT06195267·500 enrolled

Acute Respiratory Distress Syndrome1 trial

Efficacy and Safety of Sivelestat in Preventing Postoperative Acute Lung Injury or Acute Respiratory Distress Syndrome After Cardiac Surgery

Completed·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 3·NCT06276569·382 enrolled

Sepsis1 trial

PALETTE- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial

Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT06381661·2,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Sivelestat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sivelestat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sivelestat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Eli Lilly

Sivelestat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2031

Trials by Indication[1]

Acute Lung Injury1 trial

Cardiovascular Surgery1 trial

Acute Respiratory Distress Syndrome1 trial

Sepsis1 trial

References

Drug Info

Quick Facts

Related News